RSVP now to secure your spot in one of the GHS Industry Symposia sessions.



Presented by

Title: GSK Looking to the future of hepatitis B: Why should we aim for functional cure?

Join our esteemed panel of experts to explore the real-world unmet needs for people living with chronic hepatitis B and understand the potential impact the advent of functional cure could have at the level of everyday patient care.


Danjuma Adda is a Hepatitis B patient, advocate and a voice for poor populations. He was infected with Hep B while in clinical rotations and then lost his own mother to the disease several years later. He has a background in microbiology, and an MPH, with over 15 years-experience in public health and advocacy. Danjuma in 2021 assumed the role of President, World Hepatitis Alliance (WHA), UK. His local charity in Nigeria also works in the area of HIV/AIDS prevention and care, patient safety and antimicrobial resistance and stewardship in Nigeria, working to raise awareness and health care worker’s education to reduce the burden of antimicrobial resistance in Nigeria. Danjuma is a Senior Fellow with ASPEN Institute, US; Technical Advisor/Member of the World Health Organizations (WHO) Strategic and Advisory Committee on HIV, Viral Hepatitis and STIs (STAC-HHS); Executive Board Member Coalition for Global Hepatitis Elimination (CGHE) at the Global Task Force for Hepatitis US CDC; Member AMR Advisory Group of the AMR Patient Alliance; and member of several global networking groups and an accomplished Public Speaker. Danjuma is a leading voice for Hepatitis patients in Nigeria and uses his platform to advocate for the most vulnerable populations across Africa. Danjuma wants to change the narrative about Hepatitis and raise awareness about the deadliness of the disease, while also promoting other health outcomes such as antimicrobial stewardship and patient safety.

Dr Chari Cohen is President of the Hepatitis B Foundation. For the past 22 years, she has planned, implemented and evaluated community programs and research projects focusing on reducing health disparities and improving health outcomes associated with hepatitis B and liver cancer. Dr. Cohen is co-chair of the national Hep B United coalition, co-founder and chair of Hep B United Philadelphia, co-founder and chair of CHIPO: Coalition Against Hepatitis for People of African Origin; co-chair of the Hep Free PA coalition; and chair of the Sidney Kimmel Cancer Center Community Advisory Board. She is a member of the ICE-HBV steering committee, the HepVu advisory committee, and is a member of the HBV Forum for Collaborative Research and the Patient Advocacy Group of the American Association for the Study of Liver Diseases (AASLD). Dr. Cohen is Professor at the Baruch S. Blumberg Institute, and adjunct faculty for Geisinger Commonwealth School of Medicine. She received her DrPH in Community Health and Prevention from Drexel University and her MPH from Temple University.

Dr Ahmed El Sharkawy has been a consultant transplant hepatologist at the Queen Elizabeth Hospital in Birmingham since 2012. He is also honorary senior lecturer at the University of Birmingham and a Fellow of the Royal College of Physicians of London. His clinical interests include viral hepatitis, liver transplantation, polycystic liver disease, drug induced liver injury, primary biliary cholangitis, acute liver failure, acute on chronic liver failure, NAFLD (especially in the context of hepatitis B) and cirrhotic sarcopaenia. He has pioneered novel approaches to the management of hepatitis C in the community. He was awarded his PhD from Newcastle University on the role of NF-kB in the hepatic inflammation-fibrosis-cancer axis. He is a research active NHS clinician and is PI on a number of trials including a NIHR Liver Research Partnership on HBV Patient Engagement. He is the EASL Internal Affairs Councillor, Treasurer of BASL and Clinical Lead of the BASL HBV SiG. He is keen on promoting the role of social media, in particular Twitter, in medical education.

Professor Victor de Lédinghen MD PhD is Professor of Hepatology and is currently Head of the Hepatology and Liver Transplantation Unit, Haut Lévêque Hospital, University Hospital of Bordeaux, Pessac, France. Victor de Lédinghen graduated at Bordeaux University, and Cornell University (New York, USA) with a Hepato-Gastroenterology Degree and Medical Degree in 1993, and PhD in 2001. In 2003, he became Professor in Hepatology at the University Hospital of Bordeaux, France. Professor de Lédinghen has a long-standing interest in the non-invasive diagnosis of liver fibrosis and chronic liver diseases, and runs a clinical research programme studying the natural history of liver fibrosis, its impact upon patients and novel therapies for chronic liver diseases associated with liver fibrosis. His hepatology unit is the reference centre for all rare chronic liver diseases (PBC, PSC, Wilson’s disease…) in Nouvelle-Aquitaine (France). He supervises the clinical research programme of new drugs for nonalcoholic steatohepatitis (NASH) and HBV/HDV infection. His research has included participation in national and international HBV, HCV and NAFLD clinical trials, and had led to the publication of more than 300 articles in peer-reviewed journals. He supervises HBV HCV elimination in a large project “Bordeaux Metropolis without viral hepatitis”. He is a member of the European Association for the Study of the Liver, and the American Association for the Study of Liver Diseases. He is former Secretary General of the French Association for the Study of Liver Diseases (AFEF)

Associate Professor Thomas Tu is a molecular biologist and leads a research group at the Westmead Institute for Medical Research in the Storr Liver Centre (Sydney, Australia), where his team focuses on persistent forms of the Hepatitis B virus (covalently closed circular DNA and integrated HBV DNA) and develops methods to measure and eliminate them. He is particularly passionate about developing an HBV cure and mitigating the associated liver cancer, as he himself lives with chronic Hepatitis B. This provides him with unique perspectives on the disease as a researcher, patient, and advocate. He has won multiple awards for his research and outreach, most recently the 2022 Young Tall Poppy Science award. A/Prof Tu is President of the Australian Centre for Hepatitis Virology, the premier Australian society for hepatitis virus researchers. He is also the founder and Director of (a global support network for people affected with HBV), guiding people through their HBV diagnosis, and linking them with trustworthy scientific and medical information. Recently he has established Hepatitis B Voices Australia, an advocacy group run by the affected community.

Date and Time: Tuesday, April 25  12:15 – 13:15

Location: Grand Ballroom 1



Presented by

Abbvie logo

Title: Solving the HCV Elimination Puzzle: Increasing HCV Awareness and Improving Care
for Migrants.


  • The HCV Puzzle: What Have We Already ‘Pieced’ Together? (Plenary)
  • The Increased Awareness Piece: Let’s Discuss (Discussion – All Speakers)
  • The Migrant Population: Let’s Discuss (Discussion – All Speakers)
  • Finishing the Puzzle: Let’s Keep on Closing the Gaps (Plenary)
  • Increased Awareness: The Missing ‘Piece’ for HCV Reprioritization (Plenary)
  • The Increased Awareness Piece: Let’s Discuss (Discussion – All Speakers)
  • The Migrant Population: Let’s Discuss (Discussion – All Speakers)
  • The Increased Awareness Piece: Let’s Discuss (Discussion – All Speakers)
  • Migrants: An Emerging Population to Spotlight (Plenary)
  • The Migrant Population: Let’s Discuss (Discussion – All Speakers)

Date and Time: Wednesday, April 26  13:00 – 14:00

Location: Grand Ballroom 1



Welcome and Introduction

Jean-Michel Pawlotsky (Chair; FRA)

The HCV Puzzle: What Have We Already ‘Pieced’ Together? (Plenary)

Jean-Michel Pawlotsky (Chair; FRA)

Increased Awareness: The Missing ‘Piece’ for HCV Reprioritization (Plenary)

Alex Thompson (AUS)

The Increased Awareness Piece: Let’s Discuss (Discussion)

All speakers

Migrants: An Emerging Population to Spotlight (Plenary)

Victor de Ledinghen (FRA)

The Migrant Population: Let’s Discuss (Discussion)

All speakers

Finishing the Puzzle: Let’s Keep on Closing the Gaps (Plenary)

Jean-Michel Pawlotsky (Chair; FRA)



Presented by

Supported by an independent educational grant from Alexion, AstraZeneca Rare Disease.

Title: A Patient Is Waiting for a Liver Transplant: What Can We Do Now and What Could We Have Done Better? 


Date and Time: Wednesday, April 26  18:00 – 20:00

Location: Grand Ballroom 1

Karl Heinz Weiss, MD

Let’s meet 3 patients:
• Rita: patient with Hepatitis C
• Sarah: patient with Wilson Disease
• Mark: patient with non-alcoholic fatty liver disease

Jean-Michel Pawlotsky, MD, PhD; Marina Berenguer, MD; Andreas Teufel, MD, PhD; Marina Berenguer, MD

Differential diagnosis and management of a patient with liver cirrhosis: what can we do now?

Jean-Michel Pawlotsky, MD, PhD; Marina Berenguer, MD; Andreas Teufel, MD, PhD

Clinical pearls and pitfalls: What could we have done better?

Karl Heinz Weiss, MD; Jean-Michel Pawlotsky, MD, PhD; Marina Berenguer, MD, Andreas Teufel, MD, PhD

Panel discussion and audience Q&A



Presented by

Gilead logo


Title: Outlining chronic viral hepatitis: Epidemiology, overcoming challenges and patient management.

During this symposium, our expert faculty will discuss a decade of all-oral therapies for HCV, demonstrate an example of near-elimination of HCV, discuss the risk of HCC occurrence in patients with chronic HBV and highlight the impact of treatment for patients in the ‘grey zone’. The faculty will also discuss screening and treatment of HDV, and how to overcome challenges to support a future shift in the management of patients with HDV.
There will be a live Q&A session and panel roundtable discussion, during which you will have the opportunity to ask questions to the expert faculty.
We hope you will be able to join us for what promises to be an exciting and informative session!


Professor Maria Buti is Professor of Medicine at the Liver Unit and Chief of the Internal Medicine and Hepatology Department at Hospital General Universitari Valle Hebron, Barcelona, Spain. Professor Buti’s main area of interest and expertise is viral hepatitis, with experience in diagnosis and therapy of HBV and HCV. She has been an EU Policy Councillor since January 2020. She is Associate Editor on viral hepatitis for the Journal of Hepatology and an active member of EASL, AASLD and various professional societies.

Professor Jean-Michel Pawlotsky is Professor of Medicine at the University of Paris-Est, Paris, France. He is Director of the National Reference Center for Viral Hepatitis B, C and D and the Department of Virology at the Henri Mondor University Hospital, Créteil, France, as well as Director of the “Viruses-Hepatology-Cancers“ research team at the Mondor Institute of Biomedical Research (INSERM U955). He focusses on teaching and research in virology, primarily hepatitis viruses, and liver oncology.


Professor Jia-Horng Kao is Chair Professor and Distinguished Professor at the Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. He is also President of ACT-LD and Attending Physician at the Department of Internal Medicine and the Division of Gastroenterology at National Taiwan University Hospital. Professor Kao has been involved in hepatitis research for over two decades and has been a member of the APASL Steering Committee since 2012. He was the Director of the Hepatitis Research Center at National Taiwan University Hospital from 2003–2009, Secretary General of the Taiwan Association for the Study of the Liver from 2004–2005 and Vice Secretary General of the Gastroenterological Society of Taiwan from 2003–2006.

Professor Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center, Chicago, IL, USA. She has over fifteen years’ experience in hepatology, gastroenterology and internal medicine, and specialises in treating a variety of complex liver diseases, including HBV, HCV, liver cancer, liver transplantation and viral diseases. Professor Reau’s research interest lies in viral hepatitis, both in drug development and utilisation

Professor Heiner Wedemeyer has been Professor and Chair of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, Hannover, Germany since April 2020. He was previously Professor and Chair of the Department of Gastroenterology and Hepatology at University Clinic Essen, Essen, Germany from February 2018 to April 2020. Professor Wedemeyer has been involved in the scientific coordination of the German Network of Competence on Viral Hepatitis and the German Liver Foundation for more than 15 years. Currently, he serves as Managing Director of the German Hepatitis C Registry. He is a member of several scientific organisations and was Secretary General of EASL from 2009–2011.

Date and Time: Thursday, April 27  13:00 – 14:00

Location: Grand Ballroom 1



Regular registration


Late abstract submission deadline